Coave Therapeutics to Attend Upcoming Conferences
Paris, France, April 9, 2025 – Coave Therapeutics (‘Coave’), a company pioneering the future of genetic medicines, announces that members of its leadership team will be attending the following industry conferences:
- Cell & Gene Meeting on the Med – April 15-17
Rome, Italy
CEO Rodolphe Clerval will be participating in a panel discussion – Science slam: Ocular Indications – on April 15 at 13:45 CEST
Rodolphe Clerval will also give a Company Presentation on April 15 at 15:00 CEST
- ARVO (Association for Research in Vision and Ophthalmology) – May 4-8
Salt Lake City, UT, USA
- BioEquity Europe – May 12-14
Bruges, Belgium
- ASGCT (American Society of Gene and Cell Therapy) – May 13-17
New Orleans, LA, USA
***
About Coave Therapeutics
Coave Therapeutics is a genetic medicine company pioneering the development of innovative solutions to enhance the precision, safety, efficacy and manufacturability of genetic medicines. With its proprietary ALIGATER™ platform, Coave is at the forefront of addressing challenges in gene therapy delivery to extra-hepatic tissues, creating a robust pipeline targeting CNS, neuromuscular and eye diseases.
Headquartered in Paris, France, Coave Therapeutics is backed by leading international life sciences investors. For more information about the science, pipeline, and people, please visit coavetx.com and follow us on LinkedIn.
CONTACTS
Coave Therapeutics
Rodolphe Clerval, CEO
[email protected]
MEDiSTRAVA
Sylvie Berrebi, Mark Swallow
[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Crypto News Today: AlphaPepe Presale Nears Sellout With 11,000 Buyers While XRP Price Prediction Eyes $10
- Citizens Commission on Human Rights International Releases White Paper on Antidepressants and Psychiatric Drug Reform
- Investcorp Credit Management BDC, Inc. Announces Financial Results for the Quarter Ended June 30, 2026
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share